MedEdge MEA – A Memorandum of Understanding with Novartis Middle East and Department of Health Abu Dhabi
MedEdge MEA shared a post on LinkedIn:
“At Global Bio Conference 2024, the Department of Health Abu Dhabi(DoH) signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE. Under the terms of the MoU, the entities will work together to advance solutions in multiple therapeutic areas. The two priority focus areas include advancing clinical genomics research for real-world evidence (RWE) and generating and disseminating evidence to support the understanding of radioligand therapy (RLT) for cancer patients.
Thierry Diagana, Head of Global Health and California Sites Head at Novartis Biomedical Research, witnessed Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Centre at DoH, and Ibrahim Aqel, Head of Government Affairs and Value and Access – Gulf at Novartis, sign the MoU.”